Navigation Links
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
Date:11/19/2008

atient safety is our top priority, hence we have acted quickly to implement the recommendations of the DMC. Working with our development partner, Takeda, we will continue to evaluate the therapeutic potential of motesanib in non-squamous NSCLC and metastatic breast cancer, as well as in other solid tumors."

"NSCLC continues to be an area where new and effective therapies are needed. We look forward to the follow up recommendations from the DMC in order to chart the best path forward for the development of this molecule," said Nancy Simonian, M.D., chief medical officer, Millennium: The Takeda Oncology Company.

MONET1 (Motesanib NSCLC Efficacy and Tolerability Study) Trial Design

This Phase 3, multicenter, randomized, placebo-controlled, double-blind trial has enrolled 1,100 of 1,240 planned patients with advanced NSCLC. Patients with either squamous or non-squamous NSCLC were allowed in this study. Squamous NSCLC is a histological subtype of NSCLC and accounts for approximately one-third of the study population. The primary endpoint is overall survival, and secondary endpoints include progression-free survival, objective response rate in patients with measurable disease, duration of response and safety. Patients were randomized 1:1 to receive carboplatin and paclitaxel administered every three weeks with or without 125 mg motesanib taken daily.

About Motesanib

Co-developed by Amgen, Takeda Pharmaceutical Company, and Millennium: The Takeda Oncology Company, motesanib is an investigational, highly selective, oral agent that is being evaluated for its ability to inhibit angiogenesis by targeting vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR1-3). It is also under investigation for its potential direct anti-tumor activity by targeting a family of proteins called tyrosine kinases, including platelet-derived growth factor receptor (PDGFR), and stem cell facto
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
2. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
3. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
4. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
5. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
6. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... 23, 2014 Echo Therapeutics, Inc. (NASDAQ: ... focused on skin permeation, continuous glucose monitoring and ... Hollander has been appointed Chief Executive Officer ... than 20 years of experience in the medical ... recently served as Vice President, Business Development, Otsuka ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
(Date:12/26/2014)... 26, 2014 Pentec Health, Inc. number ... state of Pennsylvania for 2014. The awards program, created ... of its kind in the country. The program is ... Department of Community and Economic Development, the Pennsylvania State ... the Central Penn Business Journal. , Charlie ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 This is ... of the global Sterilizers industry with a focus on ... the market status of the Sterilizers manufacturers and is ... and individuals interested in the industry. This report provides ... applications and manufacturing technology. In this part, the report ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... The short film “Color of Honor” by young ... a true 9/11 hero, Welles Remy Crowther. It has been ... hours of Nuremberg International Short Film Festival and the 8th ... screenwriter and director Luciana Lagana plays the mother of ... husband, Gregory Graham - Graham plays a heroic ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... May 15 Gerson Lehrman Group, the world,s,leading ... a Web-based community devoted to providing patients with ... own healthcare.,iGuard.org provides personalized iGuard Risk Ratings, iGuard ... their experience with other registered,users who also want ...
... of healthcare and medical device experience to board ... of fast-growing ... the first and only flexible CO2 laser scalpel enabling new procedures ... to the company,s board of directors. Suennen, co-founder and,managing member of ...
... /Xinhua-PRNewswire/ -- Tiens Biotech Group (USA), Inc.,(the ,Company, or ,Tiens,), ... for the first quarter ended March 31, 2008., Revenue ... to,$16.2 million for the first quarter of 2007., Net ... or $0.05 per,share, compared to net income of $6.5 million, ...
... a Cranergy(TM) ... Fuel Station in NYC,s Penn Station, LAKEVILLE-MIDDLEBORO, Mass., May ... country and lift people from,America,s other energy crisis. With hectic, ... at multi-tasking, most,people need an extra boost to keep them ...
... of altruism; helping others ... one,s own health issues, CHICAGO, May 15 Meet Cindy Zamirowski, ... "cancer,free" thumbs up from her physician, stepped off the curb to raise ... The Bolingbrook mom of three and grandma of three rallied her ...
... DURHAM, N.C. -- By targeting and disabling a protein frequently ... the cancer more vulnerable to chemotherapy, according to a new ... We tested a compound that can weaken the tumor by ... cell. When chemotherapy was applied to the tumor in this ...
Cached Medicine News:Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 3Health News:Lisa M. Suennen Joins OmniGuide(R) Board of Directors 2Health News:Tiens Biotech Group (USA) Reports First Quarter Results 2Health News:Tiens Biotech Group (USA) Reports First Quarter Results 3Health News:Tiens Biotech Group (USA) Reports First Quarter Results 4Health News:Tiens Biotech Group (USA) Reports First Quarter Results 5Health News:Tiens Biotech Group (USA) Reports First Quarter Results 6Health News:Tiens Biotech Group (USA) Reports First Quarter Results 7Health News:Tiens Biotech Group (USA) Reports First Quarter Results 8Health News:Tiens Biotech Group (USA) Reports First Quarter Results 9Health News:Tiens Biotech Group (USA) Reports First Quarter Results 10Health News:Tiens Biotech Group (USA) Reports First Quarter Results 11Health News:Video: Ocean Spray Revitalizes Americans Naturally With Free Fuel for Their Bodies 2Health News:After Effects: Giving Back Is Good for You 2Health News:Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma 2
... the equivalent of 7.5 liters out of your ... need two machines for your high-flow patients! , ... Oxygen-Conserving Devices function like standard conservers, because they ... oxygen required to saturate a patient. However, ...
Proven and Efficient Stand-Alone Device. International Model. 50 psi....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
... ,Offers an average 5:1 increase in usage time ... of a standard cannula. , ,The combination ... ambulatory oxygen patients a superior alternative to liquid ... warranty. , ,NOTE: ...
Medicine Products: